AGC Biologics is seeking international regulatory approvals for its products from the FDA and EMA.
2 reports, 1 independent
Updated Jul 28
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
AGC Biologics is seeking international regulatory approvals for its products from the FDA and EMA.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
AGC Biologics
Nothing else this week.
- FDA
Related events
- FDA and Pfizer are seeking regulatory approval for their products.
- The FDA and Intellia Therapeutics are preparing a regulatory filing for product approval.
- The FDA operates under US law to evaluate international clinical data.
- Mylan is seeking regulatory approval from the FDA for new products and has listed its stock on the Nasdaq exchange.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
Coverage
Newest first; wire copies grouped- finanznachrichten.deAGC Biologics, Inc.: AGC Biologics Lands Commercial Manufacturing Agreement for Yokohama Site Worth Hundreds of Millions of Dollars